Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: GDC-0973, RG7421 (formerly XL518)
Found at BioCentury website
Every time I see a post on GDC 0973, I think back to Ohad Hammers article. More specifically this paragraph-
"Exelixis now has a second drug in pivotal studies, in development by a strong and committed partner. Roche's commitment, a large commercial opportunity, favorable deal terms and a high likelihood of clinical success, make GDC-0973 an important asset for Exelixis that is still not reflected in the company's valuation. This creates a buying opportunity, as the market will eventually acknowledge the opportunity as well as the strategic importance of GDC-0973 to Roche."
"I hope Exelixis gets a milestone for this." There was no ph 3 milestone, the rationale being that EXEL retained too large of an ownership percentage to justify a milestone. In fact, if you look at the January SEC filings, you will see that EXEL was actually presented with a bill with a 12 month due date if they want to copromote the drug.